Skip to main content
TTRX
NASDAQ Life Sciences

Turn Therapeutics Finalizes Expanded Phase 2 Design for GX-03 in Atopic Dermatitis

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$7.99
Mkt Cap
$229.07M
52W Low
$2.57
52W High
$26.5
52W Position info
211% above low
Off High info
70% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

TTRX has more than doubled off its 52-week low of $2.57 on elevated volume (2.3× avg).

Summary

Turn Therapeutics announced the final Stage 2 design for its GX-03 Phase 2 clinical trial in atopic dermatitis, expanding the patient population and optimizing statistical methodology based on positive interim data.


Key Events · Product Development and Regulatory · TTRX

  • Phase 2 Trial Design Finalized

    Turn Therapeutics completed a comprehensive interim analysis of its adaptive Phase 2 clinical trial for GX-03 in atopic dermatitis, leading to the final Stage 2 study design.

  • Patient Population Expanded

    The Stage 2 program will now prospectively evaluate patients across the full spectrum of baseline Eczema Area and Severity Index (EASI) severity, including mild-to-moderate disease (EASI 1.1-7.0), expanding the potential market.

  • Optimized Statistical Methodology

    The final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure across four prespecified efficacy endpoints, enhancing the statistical power to demonstrate significance.

  • Positive Interim Efficacy & Safety

    Clinically meaningful efficacy was observed across a broader spectrum of atopic dermatitis severity, and GX-03 continues to demonstrate a favorable safety and tolerability profile with no treatment-related serious adverse events.


Analysis · TTRX · Life Sciences

This 8-K details the refined Stage 2 design for Turn Therapeutics' lead drug candidate, GX-03, following a comprehensive interim analysis. The decision to expand the trial to include a broader spectrum of atopic dermatitis severity, including mild-to-moderate patients, significantly increases the potential market opportunity for GX-03. The optimized design, which incorporates the FDA-recognized Hochberg multiple testing procedure and enrichment for baseline pruritus severity, aims to maximize the probability of achieving statistically significant results. This update reinforces the positive momentum from previous interim Phase 2 results and indicates a clear, data-driven path forward for the drug's development.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TTRX was trading at $7.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $229.1M. The 52-week trading range was $2.57 to $26.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TTRX - Latest Insights

TTRX
Nov 10, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.79
Real-time Price: $9.35 info
Change: -$0.445 (-5%) info
Market Cap: $285.702M info
TTRX
Nov 09, 2026, 8:05 AM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $9.35 info
Change: -$0.135 (-1%) info
Market Cap: $285.702M info
TTRX
Nov 09, 2026, 8:00 AM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $9.48
Real-time Price: $9.35 info
Change: -$0.135 (-1%) info
Market Cap: $285.702M info
TTRX
Nov 09, 2026, 7:02 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $9.35 info
Change: -$0.135 (-1%) info
Market Cap: $285.702M info
TTRX
Nov 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $9.35 info
Change: -$0.135 (-1%) info
Market Cap: $285.702M info